Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter of 2008
Date:11/10/2008

- Isis ends the third quarter profitable with more than $500 million in

cash

- Conference Call Webcast Monday, November 10, 8:30 a.m. EST at

http://www.isispharm.com

CARLSBAD, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter ended September 30, 2008. Isis' positive net income for the third quarters of 2008 and 2007 was $3.2 million and $20.0 million, respectively, driven primarily by significant revenue in each period from Isis' corporate partnerships. Additionally in the last 15 months, Isis has achieved three quarters of pro forma net income, excluding non-cash stock compensation expense.

"We maintained our financial strength, ending the third quarter profitable, while remaining on track to meet our financial guidance with a net operating loss of less than $15 million for the year on a pro forma basis and year-end cash of at least $450 million. In addition to the three quarters of pro forma net income, over the last 15 months, on a pro forma basis, we have had two quarters of net operating income, with our current quarter having a very small loss at the net operating level. Although we reported another quarter of positive net income, we are not yet at the point of sustainable profitability and our quarter-to-quarter performance will continue to fluctuate based on one-time events. However, these positive financial results reflect how we are able to create significant ongoing revenue and how close the successful execution of our business model has brought us to sustainable profitability, an important goal for
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. OncoGenex Reports Third Quarter Financial Results
2. American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
4. Dendreon Reports Third Quarter 2008 Financial Results
5. Osteotech Reports 2008 Third Quarter Financial Results
6. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
7. Oncothyreon reports third quarter 2008 financial results
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. NeurogesX Reports Third Quarter 2008 Results
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
11. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... disturbance has different effects on different species of ... Universities of Bristol and Exeter which tested fish ... to a flying seagull predator model when exposed ... in European minnows. , Lead author Dr ... said: "Noise levels in many aquatic environments have ...
(Date:7/24/2014)... June 24, 2014 Some sticky research out of ... against a certain species of toxic grass fungus: moose ... month,s Biology Letters , "Ungulate saliva inhibits a ... applied to red fescue grass (which hosts a fungus ... in slower fungus growth and less toxicity. , "Plants ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Moose drool inhibits growth of toxic fungus: York U research 2
... set of proteins found in our intestines can recognize and ... surfaces, scientists at Emory University School of Medicine have discovered. ... scheduled to appear in the journal Nature Medicine . ... on the surfaces of bacteria, but these proteins are different ...
... remember the muscle shirts we wore in our teens and 20s? ... usually is obsolete. Yes, at the big 4-0 we begin to ... it may be gone. It,s an inevitable process of aging called ... A study conducted in mice with accelerated muscle loss at The ...
... scientists at the University of Missouri Center for Agroforestry ... can trap and break down veterinary antibiotics in manure ... can be effective in protecting water quality, controlling erosion ... beauty of it," said Keith Goyne, assistant professor of ...
Cached Biology News:Bacteria-killing proteins cover blood type blind spot 2Bacteria-killing proteins cover blood type blind spot 3Muscle loss finding may one day save physiques 2Plant buffers may limit spread of antibiotics in animal waste 2
... The thermostable dUTPase(pyrococcus fruriosus) ... (using proofreading DNA polymerases). It ... reactions and dNTP solutions. The ... DNA polymerase reaction can prevent dUTP ...
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Many other sizes and custom ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
Biology Products: